Human sCD30 Instant ELISA

Description: The human sCD30 Instant ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human soluble CD30 (Ki-1). The human sCD30 Instant ELISA is for research use only. Not for diagnostic or therapeutic procedures.

Characterization of the CD30 antigen has shown it to be in its mature form a transmembrane protein of about 120kDa elaborated from an 84kD cytoplasmic precursor primarily through glycosylation. The CD30 ligand (CD30L) has been identified, showing significant homology to TNF-alpha, TNF-beta, FasL, CD40L, CD27L and 4-1BBl. CD30L is expressed on activated T-cells. Interactions of the cytokine receptor CD30 with its ligand induces pleiotropic biologic effects, such as differentiation, activation, proliferation and cell death.
CD30 expression is strictly dependent on activation and proliferation of T- and B-cells. In pathological conditions, CD30 positivity is regarded as a peculiar attribute of Hodgkin's and Reed-Sternberg cells.

An 85kDa soluble form of the CD30 molecule (sCD30) has been shown to be released by CD30+ cell in vitro and in vivo. Increased serum levels of sCD30 have been reported for patients with CD30+ ALCL and CD30+ embryonal carcinoma of the testis and were found to correlate with the clinical phase of the disease, i.e. presentation complete remission (CR), relapse.

Citations: Pelzl S,Opelz G,Wiesel M,Schnlle P,Sch”nemann C,D”hler B,Ssal C.. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002;73:3-6. (Link)

Van de Graaf,E.A.; Bauwens,A.A.; Van Kessel,D.A.; Van Ginkel,W.G.J.; Otten,H.G.. Soluble CD30 is a predictor of Bronchiolitis Obliterans Syndrome after lung transplantation. Journal of Heart and Lung Transplantation 2006;25:84-84. (Link)

Wakelkamp,I.M.M.J.; Gerding,M.N.; Van Der Meer,J.W.C.; Prummel,M.F.; Wiersinga,W.M.. Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy. Clinical and Experimental Immunology 2000;121:453-457. (Link)

Bartlett,Nancy L.; Younes,Anas; Carabasi,Matthew H.; Forero,Andres; Rosenblatt,Joseph D.; Leonard,John P.; Bernstein,Steven H.; Bociek,R.Gregory; Lorenz,Jennie M.; Hart,Bruce W.; Barton,Jeremy. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008;111:1848-1854. (Link)

CARVALHO,RICARDO F.S.; ULFGREN,ANN KRISTIN; ENGSTROM,M.A.R.I.; KLINT,ERIK af; NILSSON,G.U.N.N.. CD153 in Rheumatoid Arthritis: Detection of a Soluble Form in Serum and Synovial Fluid, and Expression by Mast Cells in the Rheumatic Synovium. The Journal of Rheumatology 2009;36:501-507. (Link)

Pelzl S,Opelz G,Daniel V,Wiesel M,Ssal C.. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003;75:421-423. (Link)

Ciferska,H.; Horak,P.; Hermanova,Z.; Ordeltova,J.; Zadrazil,J.. SERUM LEVELS OF SCD30 AND SCD40L IN SLE PATIENTS. EULAR Meeting Abstracts 2006;65:195-19b. (Link)

Lee,Silvia; Macquillan,Gerry C.; Keane,Niamh M.; Flexman,James; Jeffrey,Gary P.; FRENCH,MARTYN AH; Brochier,Jean; Price,Patricia. Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin. Immunology and Cell Biology 2002;80:391-397. (Link)

Nikaein,Afzal; Spiridon,Camelia; Hunt,Judson; Rosenthal,Jed; Anderson,Allan; Eichhorn,Erick; Magee,Mitchell; Dewey,Todd; Mack,Michael. Pre-transplant level of soluble CD30 is associated with infection after heart transplantation. Clinical Transplantation 2007;21:744-747. (Link)

Heshmat,Nahla M.; El Hadidi,Eman S.. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age. Pediatric Allergy and Immunology 2006;17:297-303. (Link)

Dheda,Keertan; Chang,Jung Su; Breen,Ronan AM; Kim,Louise U.; Haddock,Jamanda A.; Huggett,Jim F.; Johnson,Margaret A.; Rook,Graham AW; Zumla,Alimuddin. In vivo and In vitro Studies of a Novel Cytokine, Interleukin-4delta2, in Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine 2005;172:200502-2278OC. (Link)

Launay,Odile; Grabar,Sophie; Bloch,Fr‚d‚ric; Desaint,Corinne; Jegou,David; Lallemand,Christophe; Erickson,Robert; Lebon,Pierre; Tovey,Michael G.. Effect of sublingual administration of interferon-[alpha] on the immune response to influenza vaccination in institutionalized elderly individuals. Vaccine 2008;26:4073-4079. (Link)

Lopez-Hoyos,M.; San Segundo,D.; Benito,M.J.; Fernandez-Fresnedo,G.; Ruiz,J.C.; Rodrigo,E.; Gomez-Alamillo,C.; Benito,A.; Arias,M.. Association Between Serum Soluble CD30 and Serum Creatinine Before and After Renal Transplantation. Transplantation Proceedings 2008;40:2903-2905. (Link)

Sanders,J.-S.F.; Huitma,M.G.; Kallenberg,C.G.M.; Stegeman,C.A.. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse. Annals of the Rheumatic Diseases 2006;65:1484-1489. (Link)

Weimer,Rolf; Staak,Anne; Susal,Caner; Streller,Sabine; Yildiz,Sevgi; Pelzl,Steffen; Renner,Fabrice; Dietrich,Hartmut; Daniel,Volker; Rainer,Lucy; Kamali-Ernst,Shirin; Ernst,Wolfgang; Padberg,Winfried; Opelz,Gerhard. ATG induction therapy: long-term effects on Th1 but not on Th2 responses. Transplant International 2005;18:226-236. (Link)

Birmann,Brenda M.; Mueller,Nancy; Okayama,Akihiko; Hsieh,Chung Cheng; Tachibana,Nobuyoshi; Tsubouchi,Hirohito; Lennette,Evelyne T.; Harn,Donald; Stuver,Sherri. Serologic Assessment of Type 1 and Type 2 Immunity in Healthy Japanese Adults. Cancer Epidemiology Biomarkers & Prevention 2004;13:1385-1391. (Link)

Ssal C,Pelzl S,Opelz G. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation. 2003;76:1231-1232. (Link)

Ssal,Caner; Pelzl,Steffen; Dohler,Bernd; Opelz,Gerhard. Identification of Highly Responsive Kidney Transplant Recipients Using Pretransplant Soluble CD30. Journal of the American Society of Nephrology 2002;13:1650-1656. (Link)

Rossi,F.M.; Degan,M.; Mazzocut-Zecchin,L.; Di Francia,R.; Aldinucci,D.; Pinto,A.; Gattei,V.. CD30L up-regulates CD30 and IL-4 expression by T cells. FEBS Letters 2001;508:418-422. (Link)

Nishioka,C.; Ikezoe,T.; Yang,J.; Koeffler,H.; Taguchi,H.. Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T cells via inhibition of the nuclear factor-[kappa]B signal pathway. Leukemia 2007;21:1044-1049. (Link)

Vaidya,Smita; Partlow,David; Barnes,Titus; Thomas,Phillip; Gugliuzza,Kristin. Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies. Clinical Transplantation 2006;20:461-464. (Link)

Weimer,R.; Susal,C.; Yildiz,S.; Streller,S.; Pelzl,S.; Staak,A.; Renner,F.; Dietrich,H.; Daniel,V.; Feuring,E.. sCD30 and Neopterin as Risk Factors of Chronic Renal Transplant Rejection: Impact of Cyclosporine A, Tacrolimus, and... Transplantation Proceedings 2005;37:1776-1778. (Link)

Weimer,R.; Susal,C.; Yildiz,S.; Staak,A.; Pelzl,S.; Renner,F.; Dietrich,H.; Daniel,V.; Kamali-Ernst,S.; Ernst,W.; Padberg,W.; Opelz,G.. Post-Transplant sCD30 and Neopterin as Predictors of Chronic Allograft Nephropathy: Impact of Different Immunosuppressive Regimens. American Journal of Transplantation 2006;6:1865-1874. (Link)

LEE,S.I.L.V.; WATSON,MARK W.; CLARK,B.E.N.; FLEXMAN,JAMES P.; CHENG,W.E.N.D.; FRENCH,MARTYN AH; PRICE,P.A.T.R.. Hepatitis C virus genotype and HIV coinfection affect cytokine mRNA levels in unstimulated PBMC but do not shift the T1/T2 balance. Immunology and Cell Biology 2006;84:390-395. (Link)

Holzer,Gerold; Pfandlsteiner,Thomas; Blahovec,Harald; Trieb,Klemens; Kotz,Rainer. Serum Concentrations of sCD30 and sCD40L in Patients with Malignant Bone Tumours. Wiener Medizinische Wochenschrift 2003;153:40-42. (Link)

References: Schwab,U.; Stein,H.; Gerdes,J.; Lemke,H.; Kirchner,H.; Schaadt,M.; Diehl,V.. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982;299:65-67. (Link)

Hansen,H.P.; Kisseleva,T.; Kobarg,J.; Horn-Lohrens,O.; Havsteen,B.; Lemke,H.. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Int.J.Cancer 1995;63:750-756. (Link)

Nadali,G.; Vinante,F.; Stein,H.; Todeschini,G.; Tecchio,C.; Morosato,L.; Chilosi,M.; Menestrina,F.; Kinney,M.C.; Greer,J.P.; .. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. J.Clin.Oncol. 1995;13:1355-1360. (Link)

Smith,C.A.; Gruss,H.J.; Davis,T.; Anderson,D.; Farrah,T.; Baker,E.; Sutherland,G.R.; Brannan,C.I.; Copeland,N.G.; Jenkins,N.A.; .. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993;73:1349-1360. (Link)

Vinante,F.; Morosato,L.; Siviero,F.; Nadali,G.; Rigo,A.; Veneri,D.; de,Sabata D.; Vincenzi,C.; Chilosi,M.; Semenzato,G.; .. Soluble forms of p55-IL-2R alpha, CD8, and CD30 molecules as markers of lymphoid cell activation in infectious mononucleosis. Haematologica 1994;79:413-419. (Link)

Nawrocki,J.F.; Kirsten,E.S.; Fisher,R.I.. Biochemical and structural properties of a Hodgkin's disease-related membrane protein. J.Immunol. 1988;141:672-680. (Link)

Latza,U.; Foss,H.D.; Durkop,H.; Eitelbach,F.; Dieckmann,K.P.; Loy,V.; Unger,M.; Pizzolo,G.; Stein,H.. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. Am.J.Pathol. 1995;146:463-471. (Link)

Stein,H.; Mason,D.Y.; Gerdes,J.; O'Connor,N.; Wainscoat,J.; Pallesen,G.; Gatter,K.; Falini,B.; Delsol,G.; Lemke,H.; .. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-858. (Link)

Gruss,H.J.; Boiani,N.; Williams,D.E.; Armitage,R.J.; Smith,C.A.; Goodwin,R.G.. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994;83:2045-2056. (Link)

Farrah,T.; Smith,C.A.. Emerging cytokine family. Nature 1992;358:26(Link)

Clark,E.A.; Ledbetter,J.A.. How B and T cells talk to each other. Nature 1994;367:425-428. (Link)

Froese,P.; Lemke,H.; Gerdes,J.; Havsteen,B.; Schwarting,R.; Hansen,H.; Stein,H.. Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. J.Immunol. 1987;139:2081-2087. (Link)

Gerli,R.; Muscat,C.; Bistoni,O.; Falini,B.; Tomassini,C.; Agea,E.; Tognellini,R.; Biagini,P.; Bertotto,A.. High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints 44. Clin.Exp.Immunol. 1995;102:547-550. (Link)

Falini,B.; Pileri,S.; Pizzolo,G.; Durkop,H.; Flenghi,L.; Stirpe,F.; Martelli,M.F.; Stein,H.. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995;85:1-14. (Link)

Durkop,H.; Latza,U.; Hummel,M.; Eitelbach,F.; Seed,B.; Stein,H.. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992;68:421-427. (Link)

Caligaris-Cappio,F.; Bertero,M.T.; Converso,M.; Stacchini,A.; Vinante,F.; Romagnani,S.; Pizzolo,G.. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin.Exp.Rheumatol. 1995;13:339-343. (Link)

Fonatsch,C.; Latza,U.; Durkop,H.; Rieder,H.; Stein,H.. Assignment of the human CD30 (Ki-1) gene to 1p36. Genomics 1992;14:825-826. (Link)

Smith,C.A.; Farrah,T.; Goodwin,R.G.. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994;76:959-962. (Link)

Josimovic-Alasevic,O.; Durkop,H.; Schwarting,R.; Backe,E.; Stein,H.; Diamantstein,T.. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur.J.Immunol. 1989;19:157-162. (Link)

Stein,H.; Gerdes,J.. [Phenotypic and genotypic marker in malignant lymphomas: cellular origin of Hodgkin's disease and malignant histiocytosis as well as implications for classifying T-cell and B-cell lymphomas]. Verh.Dtsch.Ges.Pathol. 1986;70:127-151. (Link)